LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.46M | 2.36M | 2.35M | -1.80M | -2.09M |
| Total Depreciation and Amortization | 1.52M | 1.26M | 1.10M | 939.40K | 938.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.66M | -1.62M | -1.75M | 3.71M | 3.68M |
| Change in Net Operating Assets | -633.20K | -1.47M | -2.93M | -4.40M | -5.83M |
| Cash from Operations | 1.68M | 530.70K | -1.24M | -1.55M | -3.29M |
| Capital Expenditure | -714.10K | -1.08M | -1.19M | -2.05M | -1.31M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -822.10K | -2.36M | -2.36M | -1.56M | -1.54M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.29M | -2.04M | -1.87M | -607.70K | -503.90K |
| Cash from Investing | -3.82M | -5.48M | -5.42M | -4.22M | -3.35M |
| Total Debt Issued | 17.39M | 12.20M | 9.69M | 4.24M | 5.42M |
| Total Debt Repaid | -6.24M | -6.66M | -6.46M | -3.74M | -2.94M |
| Issuance of Common Stock | 960.00K | 6.25M | 8.23M | 8.23M | 7.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.00M | -2.30M | -2.07M | -696.00K | -973.00K |
| Cash from Financing | 7.24M | 6.81M | 6.87M | 5.91M | 6.47M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.09M | 1.87M | 207.60K | 141.20K | -173.50K |